Immunic Overview
Valuation check: IMUX's ROE is -87.45%, below the Healthcare sector average of 21.28%.
Get informed when a big investor buys or sells
+ Follow-87.45%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
Immunic (IMUX) currently reports a ROE of -87.45%. That is below the Healthcare sector average of 21.28%. Use the charts on this page to explore Immunic's ROE history and peer comparisons.
Immunic's ROE of -87.45% is lower than the Healthcare sector average of 21.28%. That is roughly 510.9% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.
There is no universal 'good' ROE, but Immunic's current -87.45% should be judged against Healthcare norms (sector average: 21.28%) and against IMUX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.
Start with the current ROE of -87.45%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.28%. From there, open related valuation or income-statement pages for Immunic, and consider following IMUX for alerts when major investors trade the stock.
Immunic is classified in the Healthcare sector. On ROE, it currently shows -87.45% versus a sector average near 21.28%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing IMUX with unrelated industries.
